Navigation Links
Newbridge Securities Corporation Forms BioVentures Division
Date:2/17/2009

Newbridge Expands its Presence in the Biotech Industry

FT. LAUDERDALE, Fla., Feb. 17 /PRNewswire/ -- Newbridge Securities Corporation ("Newbridge"), a full-service securities broker-dealer and investment bank, is proud to announce the formation of the Newbridge BioVentures Division ("NBV"). NBV is dedicated to providing investment banking services for the biotech industry and related investment opportunities for institutional and sophisticated individual investors.

We are pleased to announce Christopher Carra as the Managing Director of NBV. Mr. Carra has been a registered representative in the securities industry for over 16 years, primarily focused in the biotech sector. Mr. Carra has been involved in several private placements and initial public offerings for biotech companies, and is a founding member of NBV. Prior to joining Newbridge in 2005, Mr. Carra worked at several private-client focused firms, most recently Oppenheimer & Co., where he worked from 2000-2005 as a senior vice president.

Please visit the BioVentures website; it can be accessed through www.newbridgesecurities.com or www.investbiopharma.com.

"We are extremely excited to add NBV as a focus to our already diversified suite of businesses," said Guy S. Amico, Newbridge's president. "In addition, having powerful advisors, such as Dr. David Sherris, Ph.D., on the Scientific Advisory board will lend top-level credibility and research to enhance our success rate for our Institutional and Private Client Group clients."

About Newbridge

Newbridge Securities Corporation provides full service securities brokerage and investment banking services to a broad based group of individuals and corporate clients. Comprised of a committed and experienced team of financial service professionals, we seek to empower our clients to build and preserve wealth by providing superior financial services and products.

For more information on NBV, contact Christopher Cara at 561.391.1220 (email at ccara@newbridgesecurities.com) or visit our website at www.newbridgesecurities.com.


'/>"/>
SOURCE Newbridge Securities Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MINRAD Receives Notice That NYSE Alternext Intends to File Delisting Application With Securities and Exchange Commission
2. deCODE Sells Auction Rate Securities
3. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
4. Credit Suisse Repurchases Auction Rate Securities (ARS) From Rosetta Genomics
5. Isolagen to Present at the JMP Securities Healthcare Focus Conference
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference
7. ARCA biopharma to Present at JMP Securities Healthcare Focus Conference
8. Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference
9. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
10. NxStage Medical to Present at JMP Securities Healthcare Focus Conference
11. Genomic Health to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... and Liege, Belgium (PRWEB) , ... January 17, ... ... solutions for sample preparation and epigenetics research, recently announced a collaboration with the ... a high-sensitivity DNA amplification method for library preparation, following the company’s successful launch ...
(Date:1/16/2017)... --  Valentin A. Pavlov, PhD , associate investigator, and ... of The Feinstein Institute for Medical Research ... nervous system regulates the immune system, which will help ... devices to treat disease and injury. The analysis is ... The paper examines various studies which further define the ...
(Date:1/14/2017)... , Jan. 13, 2017  The Alliance for Safe ... response to FDA final guidance on biologic ... continued leadership in emphasizing the importance of distinct naming ... aware of the benefits biosimilars will bring to patients, ... Yet the portion of the Guidance dealing with ...
(Date:1/13/2017)... ... 13, 2017 , ... FireflySci has been busy rolling out ... diverse customer base. The latest entry in this field is a series of ... Bio-Rad. FireflySci is introducing three distinct varieties including a 10x1mm, 10x2 and 10x4 ...
Breaking Biology Technology:
(Date:12/16/2016)... YORK , Dec. 16, 2016 The global wearable ... USD 12.14 billion by 2021 from USD 5.31 billion in 2016, ... ... is mainly driven by technological advancements in medical devices, launch of ... rising preference for wireless connectivity among healthcare providers, and increasing focus ...
(Date:12/15/2016)... DUBLIN , Dec 15, 2016 ... Research and Markets has announced ... to their offering. The report forecasts the global military ... 2016-2020. The report has been prepared based on an ... market landscape and its growth prospects over the coming years. The report ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the growth of ... expected to grow from USD 4.03 billion in 2015 ... of 29.3% between 2016 and 2022. The market is ... smart devices, government initiatives, and increasing penetration of e-commerce ... to grow at a high rate during the forecast ...
Breaking Biology News(10 mins):